Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development by Year
Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M) ($M)
Vertex Pharmaceuticals Development: $1,494M in FY2025, up 20.5% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Outsourced services and other direct expenses | 1,493.5 | 21% | 1,239.1 | 0% | 1,238.7”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,494 | +20.5% | Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 1,239 | 0.0% | Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,239 | +35.7% | Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 913 | +45.0% | Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 629 | +22.9% | Form 10-K (vrtx-20231231.htm, filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 512 | +20.5% | Form 10-K (vrtx-20221231.htm, filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 425 | -9.8% | Form 10-K (vrtx-20211231.htm, filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 471 | +18.7% | Form 10-K (vrtx-20201231.htm, filed 2021-02-11) ↗ |
| FY2017 | Dec 31, 2017 | 397 | – | Form 10-K (a201910k-main.htm, filed 2020-02-13) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development ($M), annual FY2017–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-outsourced
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.